PEDRO
PÉREZ SEGURA
Profesor asociado de Ciencias de la Salud
Alfonso
Berrocal Jaime
Publicacions en què col·labora amb Alfonso Berrocal Jaime (10)
2020
-
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861
2019
-
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
The Lancet, Vol. 393, Núm. 10167, pp. 156-167
2018
-
Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1529-1537
2016
-
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579
2015
-
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
Clinical and Translational Oncology, Vol. 17, Núm. 9, pp. 743-750
2014
-
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
Journal of Neuro-Oncology, Vol. 116, Núm. 2, pp. 413-419
-
Erratum: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [J Neurooncol, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y]
Journal of Neuro-Oncology
2012
-
SEOM guideline for the treatment of malignant glioma
Clinical and Translational Oncology, Vol. 14, Núm. 7, pp. 545-550
2010
-
Extended-schedule dose-dense temozolomide in refractory gliomas
Journal of Neuro-Oncology, Vol. 96, Núm. 3, pp. 417-422